Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma.

Satoshi NodaHiroya IidaTakehide FujimotoYoshinori WakasugiNaoki YabutaMasatomo SudouDaiki HiraMasaji TaniAkira AndohShin-Ya MoritaTomohiro Terada

Published in: Cancer chemotherapy and pharmacology (2021)

Considering these results, we propose that the target trough concentration of lenvatinib could be 36.8-71.4 ng/mL for maintaining disease control status and reducing grade ≥ 3 toxicity in the treatment of HCC.

Keyphrases

combination therapy